Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) | Finanzwire

Basculer en Français

10925	Companies
238417	Keywords
167224	Articles
128086	Press releases

Headlines Articles Press releases Aspire Biopharma Holdings, Inc.

Home
Companies
Aspire Biopharma Holdings, Inc.

BRIEF

published on 08/13/2026 at 14:20, 20 days 21 hours ago

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Acquisition Investor Conference Biopharma Sublingual Technology Dura Driver
PRESS RELEASE

published on 08/13/2026 at 14:15, 20 days 22 hours ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
Aspire Biopharma to attend Sidoti Micro-Cap Virtual Investor Conference on August 19-20, 2026. Management to discuss clinical pipeline and recent acquisition of Dura Driver Control Systems

Virtual Investor Conference Clinical Pipeline Aspire Biopharma Sidoti Dura Driver Control Systems
BRIEF

published on 12/04/2025 at 15:05, 8 months 29 days ago

Aspire Biopharma Reports Q3 2025 Business Developments

FDA Submission Sublingual Technology Aspire Biopharma BUZZ BOMB™ Q3 2025 Update
PRESS RELEASE

published on 12/04/2025 at 15:00, 8 months 29 days ago

Aspire Biopharma Provides Q3 2025 Business Update
Aspire Biopharma updates Q3 2025 progress, including FDA submission, patent application, and BUZZ BOMB™ launch. Anticipates NDA for sublingual aspirin in H1 2026

Patent Application FDA Submission Aspire Biopharma BUZZ BOMB™ Launch NDA 2026
BRIEF

published on 12/02/2025 at 15:05, 9 months ago

Aspire Biopharma Advances FDA Discussions for Sublingual Aspirin

FDA Submission Clinical Trial Results Aspire Biopharma Sublingual Aspirin Heart Attack Treatment
PRESS RELEASE

published on 12/02/2025 at 15:00, 9 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire Biopharma Holdings, Inc. submits Pre-IND meeting request to FDA for fast-acting sublingual aspirin formulation to treat acute myocardial infarction, demonstrating rapid action and potential for FDA approval

Clinical Trial FDA Submission Aspire Biopharma Sublingual Aspirin Acute Myocardial Infarction
BRIEF

published on 11/26/2025 at 15:05, 9 months 6 days ago

Aspire Biopharma Strengthens Team with New Appointment

Sublingual Delivery Aspire Biopharma Dr. Mark J. Jaroszeski DNA/drug Innovation Scientific Team
PRESS RELEASE

published on 11/26/2025 at 15:00, 9 months 6 days ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
Aspire Biopharma appoints Dr. Mark J. Jaroszeski, PhD as a key addition to its scientific team, enhancing drug delivery technology development and innovation

Drug Delivery Technology Sublingual Delivery Aspire Biopharma Mark J. Jaroszeski Medical Engineering
BRIEF

published on 11/06/2025 at 15:05, 9 months 26 days ago

Aspire Biopharma Initiates Partnership Discussions at CPHI Frankfurt

Pharmaceutical Partnerships Drug Delivery Technology Aspire Biopharma Sublingual Aspirin CPHI Frankfurt
PRESS RELEASE

published on 11/06/2025 at 15:00, 9 months 26 days ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
Aspire Biopharma successfully participated in CPHI Frankfurt, engaging in strategic discussions with global pharma companies for its innovative sublingual high-dose aspirin. The event hosted 63,000+ attendees from 160 countries

Drug Delivery Technology Aspire Biopharma CPHI Frankfurt Sublingual High-dose Aspirin Pharmaceutical Event

Accesswire

Published on 09/03/2026 at 12:00, 18 minutes ago

NuRAN Wireless Announces Creation of NuEnergy, a Solar, Storage and Hybrid Power Subsidiary
Published on 09/02/2026 at 22:55, 13 hours 23 minutes ago

Secure Blockchain Sells Delivery Trust(R) Business
Published on 09/02/2026 at 18:45, 17 hours 33 minutes ago

Full Circle Lithium Rebrands as FCL-X Fire & Safety Inc. and Provides Corporate Update
Published on 09/02/2026 at 15:00, 21 hours 18 minutes ago

Vox Royalty Enters into Binding Agreement to Acquire the White Dam Gold Royalty in Australia
Published on 09/02/2026 at 14:30, 21 hours 48 minutes ago

Solitario Completes Phase-One Drilling at Golden Crest - Reports Initial Drill Results for Ponderosa

View all ACCESSWIRE

EQS Group

Published on 09/03/2026 at 12:05, 13 minutes ago

EXIN launches the AI Security Professional certification, built on the OWASP AI Exchange -- making AI security skills transparent and verifiable
Published on 09/03/2026 at 11:45, 33 minutes ago

Gan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe
Published on 09/03/2026 at 11:30, 48 minutes ago

u-blox enhances GNSS timing validation with nanosecond-accurate METAS time service
Published on 09/03/2026 at 11:30, 48 minutes ago

Four Years of Partnership, Striving for Excellence | XTrend Speed × AFA Renew Sponsorship for the Fourth Consecutive Year
Published on 09/03/2026 at 11:00, 1 hour 18 minutes ago

ABB Ltd: ABB share buybacks - August 27, 2026 - September 2, 2026

Les Echos

Published on 09/03/2026 at 07:00, 5 hours 18 minutes ago

Excellent portfolio performance leads to a 7.5% increase in Net Asset Value to EUR 57.2 per share
Published on 09/02/2026 at 21:30, 14 hours 48 minutes ago

Accor announces the success of OCEANEs due 2032 for a nominal amount of €380 million and the results of the partial repurchase of its outstanding OCEANEs due 2027
Published on 09/02/2026 at 18:20, 17 hours 58 minutes ago

Appointment to Edenred’s Executive Committee
Published on 09/02/2026 at 18:00, 18 hours 18 minutes ago

Outstanding shares and voting rights statement at 31 August 2026
Published on 09/02/2026 at 17:45, 18 hours 33 minutes ago

Disclosure of shares outstanding and voting rights - 02.09.2026

View all LES ECHOS COMFI WIRE